Predictors of serofast state after treatment for early syphilis in HIV-infected patients.
HIV
corticosteroid
non-treponemal
serofast
syphilis
Journal
HIV medicine
ISSN: 1468-1293
Titre abrégé: HIV Med
Pays: England
ID NLM: 100897392
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
21
04
2020
revised:
25
07
2020
accepted:
23
09
2020
pubmed:
1
11
2020
medline:
15
3
2022
entrez:
31
10
2020
Statut:
ppublish
Résumé
Non-treponemal serological tests are used to monitor treatment response during syphilis infection. Syphilis- and HIV-coinfected patients may experience incomplete resolution in non-treponemal titres, which is referred to as the serofast state. The goal of this study was to evaluate risk factors for serofast state in HIV-infected patients. From November 2015 to June 2018, 1530 HIV-positive patients were tested for syphilis using a Treponema pallidum particle agglutination (TPPA) assay. Among TPPA-positive patients, medical records were reviewed for early syphilis infection. Serofast state was defined as a less than four-fold decrease in non-treponemal antibody titres during a 6-month follow-up period in the absence of symptoms of syphilis. Baseline characteristics were tested as predictive factors of serological response. In all, 515 patients (33.7%) tested positive in TPPA assays, and in 163 patients at least one previous syphilis infection was documented. A total of 61 out of 163 patients (37.4%) were in a serofast state. A history of previous syphilis infection (61 vs. 43%; P = 0.04) was more common in serofast patients than in patients with serological cure after 6 months. Non-treponemal titres ≥ 1:32 before therapy (47 vs. 25%; P = 0.005) and adjunctive corticosteroids to prevent the Jarisch-Herxheimer reaction (35% vs 15%; P = 0.006) were associated with serological cure after 6 months, but corticosteroid therapy had no influence at 12 months. The intensity of syphilis treatment did not affect serological cure. Corticosteroids for prevention of the Jarisch-Herxheimer reaction were associated with earlier serological cure. Although serological response is the accredited surrogate method to monitor syphilis treatment, the biological significance of the serofast state remains unclear.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
165-171Informations de copyright
© 2020 The Authors. HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association.
Références
Jansen K. Syphilis in Deutschland im Jahr 2018 - Anstieg der Vorjahre stagniert auf hohem Niveau. Epid Bull 2019; 50 (50): 545-554.
European Centre for Disease Prevention and Control (ECDC). Syphilis - Annual Epidemiological Report for 2017. ECDC, 2019.
Arando M, Fernandez-Naval C, Mota-Foix M et al. Early syphilis: risk factors and clinical manifestations focusing on HIV-positive patients. BMC Infect Dis 2019; 19 (1): 727.
Janier M, Hegyi V, Dupin N et al. 2014 European guideline on the management of syphilis. J Eur Acad Dermatol Venereol JEADV 2014; 28 (12): 1581-1593.
Workowski KA, Bolan GA, Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines. MMWR Recomm Rep Morb Mortal Wkly Rep Recomm Rep 2015; 64 (RR-03): 1-137.
Hook EW. Syphilis. Lancet Lond Engl 2017; 389 (10078): 1550-1557.
Ghanem KG, Erbelding EJ, Wiener ZS, Rompalo AM. Serological response to syphilis treatment in HIV-positive and HIV-negative patients attending sexually transmitted diseases clinics. Sex Transm Infect 2007; 83 (2): 97-101.
Jinno S, Anker B, Kaur P, Bristow CC, Klausner JD. Predictors of serological failure after treatment in HIV-infected patients with early syphilis in the emerging era of universal antiretroviral therapy use. BMC Infect Dis 2013; 13: 605.
Ghanem KG, Moore RD, Rompalo AM, Erbelding EJ, Zenilman JM, Gebo KA. Antiretroviral therapy is associated with reduced serologic failure rates for syphilis among HIV-infected patients. Clin Infect Dis Off Publ Infect Dis Soc Am 2008; 47 (2): 258-265.
Tsai J-C, Lin Y-H, Lu P-L et al. Comparison of serological response to doxycycline versus benzathine penicillin G in the treatment of early syphilis in HIV-infected patients: a multi-center observational study. PLoS One 2014; 9 (10): e109813.
Seña AC, Zhang X-H, Li T et al. A systematic review of syphilis serological treatment outcomes in HIV-infected and HIV-uninfected persons: rethinking the significance of serological non-responsiveness and the serofast state after therapy. BMC Infect Dis 2015; 15: 479.
Seña AC, Wolff M, Behets F et al. Response to therapy following retreatment of serofast early syphilis patients with benzathine penicillin. Clin Infect Dis Off Publ Infect Dis Soc Am 2013; 56 (3): 420-422.
Andrade R, Rodriguez-Barradas MC, Yasukawa K, Villarreal E, Ross M, Serpa JA. Single dose versus 3 doses of intramuscular benzathine penicillin for early syphilis in HIV: a randomized clinical trial. Clin Infect Dis Off Publ Infect Dis Soc Am 2017; 64 (6): 759-764.
Yang C-J, Lee N-Y, Chen T-C et al. One dose versus three weekly doses of benzathine penicillin G for patients co-infected with HIV and early syphilis: a multicenter, prospective observational study. PLoS One 2014; 9 (10): e109667.
Arando M, Fernandez-Naval C, Mota-Foix M et al. The Jarisch-Herxheimer reaction in syphilis: could molecular typing help to understand it better? J Eur Acad Dermatol Venereol JEADV 2018; 32 (10): 1791-1795.
Butler T. The Jarisch-Herxheimer reaction after antibiotic treatment of spirochetal infections: a review of recent cases and our understanding of pathogenesis. Am J Trop Med Hyg 2017; 96 (1): 46-52.
Tsai M-S, Yang C-J, Lee N-Y et al. Jarisch-Herxheimer reaction among HIV-positive patients with early syphilis: azithromycin versus benzathine penicillin G therapy. J Int AIDS Soc 2014; 17: 18993.
Yang C-J, Lee N-Y, Lin Y-H et al. Jarisch-Herxheimer reaction after penicillin therapy among patients with syphilis in the era of the hiv infection epidemic: incidence and risk factors. Clin Infect Dis Off Publ Infect Dis Soc Am 2010; 51 (8): 976-979.
Pound MW, May DB. Proposed mechanisms and preventative options of Jarisch-Herxheimer reactions. J Clin Pharm Ther. 2005; 30 (3): 291-295.
Angel-Müller E, Grillo-Ardila CF, Amaya-Guio J, Torres-Montañez NA, Vasquez-Velez LF. Point of care rapid test for diagnosis of syphilis infection in men and nonpregnant women. Cochrane Database Syst Rev 2018; 2018 (5): CD013036.
Pastuszczak M, Kotnis-Gąska A, Jakubowicz B, Martyka I, Bociaga-Jasik M, Wojas-Pelc A. Utility of antitreponemal IgM testing in the diagnosis of early and repeat syphilis among HIV-infected and non-infected patients. Int J STD AIDS 2018; 29 (9): 890-894.
Hamill MM, Mbazira KJ, Kiragga AN et al. Challenges of RPR interpretation in syphilis screening in Uganda: variability in non-treponemal results between different laboratories. Sex Transm Dis 2018; 45 (12): 829-833.
Rolfs RT, Joesoef MR, Hendershot EF et al. A randomized trial of enhanced therapy for early syphilis in patients with and without human immunodeficiency virus infection. the syphilis and HIV Study Group. N Engl J Med 1997; 337 (5): 307-314.
Ghanem KG, Workowski KA. Management of adult syphilis. Clin Infect Dis Off Publ Infect Dis Soc Am 2011; 53 (Suppl 3): S110-S128.
Knaute DF, Graf N, Lautenschlager S, Weber R, Bosshard PP. Serological response to treatment of syphilis according to disease stage and HIV status. Clin Infect Dis. 2012; 55 (12): 1615-1622.
Dionne-Odom J, Karita E, Kilembe W et al. Syphilis treatment response among HIV-discordant couples in Zambia and Rwanda. Clin Infect Dis Off Publ Infect Dis Soc Am 2013; 56 (12): 1829-1837.
Manavi K, McMillan A. The outcome of treatment of early latent syphilis and syphilis with undetermined duration in HIV-infected and HIV-uninfected patients. Int J STD AIDS 2007; 18 (12): 814-818.
Tittes J, Aichelburg MC, Antoniewicz L, Geusau A. Enhanced therapy for primary and secondary syphilis: a longitudinal retrospective analysis of cure rates and associated factors. Int J STD AIDS 2013; 24 (9): 703-711.
Luo Z, Zhu L, Ding Y et al. Factors associated with syphilis treatment failure and reinfection: a longitudinal cohort study in Shenzhen, China. BMC Infect Dis 2017; 17 (1): 620.
Malone JL, Wallace MR, Hendrick BB et al. Syphilis and neurosyphilis in a human immunodeficiency virus type-1 seropositive population: evidence for frequent serologic relapse after therapy. Am J Med 1995; 99 (1): 55-63.
Wu B-R, Tsai M-S, Yang C-J et al. Spirochetemia due to Treponema pallidum using polymerase-chain-reaction assays in patients with early syphilis: prevalence, associated factors and treatment response. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis 2014; 20 (8): O524-O527.
Fiumara NJ. Serologic responses to treatment of 128 patients with late latent syphilis. Sex Transm Dis 1979; 6 (4): 243-246.
Cai SN, Long J, Chen C, Wan G, Lun WH. Incidence of asymptomatic neurosyphilis in serofast Chinese syphilis patients. Sci Rep 2017; 7 (1): 15456.